Although there are many strategies for targeting the STAT3 signaling pathway, only indirect inhibitors, such as the JAK and tyrosine kinase inhibitors, have received FDA approval for use against rheumatoid arthritis and myeloproliferative neoplasm [15]. This evidence concerns the gene STAT3 and myeloproliferative disorder.